{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(6)"],"submitter":["Maffioli M"],"pubmed_abstract":["Ruxolitinib (RUX) is extensively used in myelofibrosis (MF). Despite its early efficacy, most patients lose response over time and, after discontinuation, have a worse overall survival (OS). Currently, response criteria able to predict OS in RUX-treated patients are lacking, leading to uncertainty regarding the switch to second-line treatments. In this study, we investigated predictors of survival collected after 6 months of RUX in 209 MF patients participating in the real-world ambispective observational RUXOREL-MF study (NCT03959371). Multivariable analysis identified the following risk factors: (1) RUX dose <20 mg twice daily at baseline, months 3 and 6 (hazard ratio [HR], 1.79; 95% confidence interval [CI], 1.07-3.00; P = .03), (2) palpable spleen length reduction from baseline ≤30% at"],"journal":["Blood advances"],"pagination":["1855-1864"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8941454"],"repository":["biostudies-literature"],"pubmed_title":["A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis."],"pmcid":["PMC8941454"],"pubmed_authors":["Guidetti A","Iurlo A","Caberlon S","Caramella M","Ubezio M","Komrokji R","Carraro MC","Mora B","Polverelli N","Della Porta MG","Lunghi F","Giorgino T","Bertu L","D'Adda M","Maffioli M","Sissa C","Rumi E","Vismara A","Anghilieri M","Kuykendall A","Finazzi MC","Passamonti F","Molteni A","Ball S","Cattaneo D","Brociner M","Elli EM"],"additional_accession":[]},"is_claimable":false,"name":"A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.","description":"Ruxolitinib (RUX) is extensively used in myelofibrosis (MF). Despite its early efficacy, most patients lose response over time and, after discontinuation, have a worse overall survival (OS). Currently, response criteria able to predict OS in RUX-treated patients are lacking, leading to uncertainty regarding the switch to second-line treatments. In this study, we investigated predictors of survival collected after 6 months of RUX in 209 MF patients participating in the real-world ambispective observational RUXOREL-MF study (NCT03959371). Multivariable analysis identified the following risk factors: (1) RUX dose <20 mg twice daily at baseline, months 3 and 6 (hazard ratio [HR], 1.79; 95% confidence interval [CI], 1.07-3.00; P = .03), (2) palpable spleen length reduction from baseline ≤30% at","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-05-09T19:51:35.433Z","creation":"2025-04-05T09:57:56.164Z"},"accession":"S-EPMC8941454","cross_references":{"pubmed":["35130339"],"doi":["10.1182/bloodadvances.2021006889"]}}